1. Home
  2. LMAT vs RARE Comparison

LMAT vs RARE Comparison

Compare LMAT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

N/A

Current Price

$81.70

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

N/A

Current Price

$15.94

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LMAT
RARE
Founded
1983
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2006
2013

Fundamental Metrics

Financial Performance
Metric
LMAT
RARE
Price
$81.70
$15.94
Analyst Decision
Buy
Buy
Analyst Count
8
21
Target Price
★ $107.00
$26.25
AVG Volume (30 Days)
232.8K
★ 3.3M
Earning Date
11-04-2026
11-03-2026
Dividend Yield
★ 1.24%
N/A
EPS Growth
★ 30.57
7.31
EPS
★ 1.42
N/A
Revenue
$249,602,000.00
★ $673,000,000.00
Revenue This Year
$10.79
$12.96
Revenue Next Year
$9.55
$31.15
P/E Ratio
$57.04
★ N/A
Revenue Growth
13.53
★ 20.13
52 Week Low
$78.22
$12.73
52 Week High
$118.01
$39.89

Technical Indicators

Market Signals
Indicator
LMAT
RARE
Relative Strength Index (RSI) 48.36 48.64
Support Level $78.35 $14.11
Resistance Level $83.15 $23.44
Average True Range (ATR) 2.35 0.74
MACD -0.09 0.25
Stochastic Oscillator 33.22 47.57

Price Performance

Historical Comparison
LMAT
RARE

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: